BHR vs STRS

The deterministic health scores paint a concerning picture, with a Piotroski F-Score of just 2/9 indicating severe financial weakness. Despite a recent short-term price rebound and a high dividend yield, BHR exhibits persistent profitability issues, negative earnings growth, and a weak balance sheet. Valuation metrics appear low but are misleading given the company's operational deterioration and lack of reliable earnings. The absence of an Altman Z-Score due to data gaps further increases uncertainty, while technical and insider signals remain deeply negative.

STRS exhibits severe fundamental deterioration, highlighted by a weak Piotroski F-Score of 2/9 and a significant disconnect between its current price ($29.90) and its growth-based intrinsic value ($10.43). While the stock trades near its Graham Number ($29.35), the company suffers from negative revenue growth (-19.4%) and a deeply negative operating margin (-51.61%), suggesting that any net profits are derived from non-core activities rather than operations. Despite strong 1-year price performance, the combination of bearish insider selling and crashing Q/Q EPS growth (-83.3%) indicates a high risk of a price correction.